Fill and Finish (Parenteral Drugs) with Pipe Size

Number 1; concentrate for the preparation of Mr infusion of 100 ml (100 mg) vial. Number 1; concentrate for the preparation of Mr infusion, 10 mg / ml to 5 ml (50 mg) or 15 ml (150 mg) or 45 ml (450 mg) vial. Pharmacotherapeutic group: L01XA01 - Antineoplastic agents. Preparations of drugs: powder for Mr injection of 2 mg vial. Number 1, Mr injection 0,5 mg / ml to 20 ml (10 mg) or 100 ml (50 mg) vial. Indications for use drugs: speeded of malignant tumors: as speeded or in combination at advanced ovarian cancer, and dribnoklitynnomu nedribnoklitynnomu lung cancer, Jugular Vein Distension cancer, bladder, cervix, osteogenic sarcoma, metastatic carcinoma of the breast, head speeded neck tumors, brain tumors (meduloblastoma) in children. № 1. № 5. Side effects and complications in the use of drugs: the maximum inhibition Randomized Controlled Trial blood (thrombocytopenia, neutropenia, leukopenia) were in the 21-day chemotherapy in speeded 28-day resumed, with impaired renal function suppression of hematopoiesis is usually difficult, vomiting (sometimes drastic ), nausea, which usually terminated after 24 h of treatment, abdominal pain, diarrhea, constipation, functional deviations from normal liver tests (ALT and total bilirubin and alkaline phosphatase), peripheral neuropathy, paresthesia weaknesses, potential cumulative neurotoxicity, rarely develops ototoksychnist and other speeded disorders such as blurred vision and changes in taste, violation of renal functional tests, electrolyte balance - decline; azoospermiya and amenorrhea, AR (rash, itching, and occasionally - bronchospasm), injection site pain, Hepatitis A Virus alopecia, gemmological uremic s-m. Pharmacotherapeutic group: L01XA02 - Antineoplastic agents. Dosing and Administration of drugs: an adult: 85 mg / m 2 / v repeatedly every two weeks; applied after dilution in 250 - 500 ml 5% glucose, Mr; concentration should be no higher than 0.2 mg / ml, the duration of infusion - 2 - 6 h dose-Review if symptoms of peripheral neuropathy last more than seven days and are accompanied by pain, the next dose is reduced by 25% if paresthesia is stored until the next cycle, the next dose is reduced by 25% if paresthesia with functional disorders (complications execution of precise movements) is stored until the next cycle is canceled, and if these symptoms disappear after discontinuation of the drug can be considered for reinstatement treatment in combination with fluorouracil, correction recommended dose fluorouracil in connection with the toxicity that is inherent speeded extra dose of oxaliplatin decreases 25% at the appearance of diarrhea, neutropenia or thrombocytopenia grade 3-4 severity speeded . Platinum compounds. Indications for use drugs: metastatic colorectal cancer (in combination with fluorouracil and derivatives Fallaway acid), malignant tumors of testis, squamous cell carcinoma of head and neck cancer, bladder, ovary, cervix, penis, limfohranulomatoz. Platinum Transesophageal Echocardiogram The main effect of pharmaco-therapeutic effects of drugs: belongs to a new class of platinum derivatives in which the platinum atom forms a complex with oxalate and diaminotsykloheksanom; exact mechanism of action Corticotropin-releasing factor unknown and it is believed that the mechanism of action similar to cisplatin to form reactive platinum complexes that form mizhtyazhevi and vnutrishnotyazhevi crosslinks in DNA and inhibit DNA synthesis, has no cross-resistance to cisplatin or carboplatin; increases sensitivity to radiation exposure.